For income investors relying on dividends, blue chip stocks offer relative safety and consistent income over the long term.

With the threat of inflation and market uncertainty due to tariffs, investors may want to opt for proven companies that have established, diversified business models.

This article will discuss 3 long-term blue-chip stocks that have raised their dividends each year for over 10 years, have current yields above 3%, and should continue to increase their dividends for years to come.

Pfizer Inc. (PFE)

Pfizer Inc. is a global pharmaceutical company focusing on prescription drugs and vaccines. Pfizer’s top products are Eliquis, Prevnar family, Paxlovid, Comirnaty, Vyndaqel family, Ibrance, and Xtandi. Pfizer had revenue of $63.6B in 2024.

Pfizer reported solid Q4 2024 results on February 4th, 2025. Company-wide revenue grew 21% operationally and adjusted diluted earnings per share climbed to $0.63 versus $0.10 on a year-over-year basis because of stabilizing COVID-19 related sales, growing revenue from the existing portfolio, and lower expenses. Global Biopharmaceuticals sales gained 22%.

Pfizer’s current product line is expected to produce top line and bottom-line growth out to 2030 because of significant R&D and acquisitions. As a result, Pfizer’s current product line is growing. Previously declining volumes and sales of Paxlovid and Comirnaty have largely stabilized.

Future growth will come from increasing sales for approved indications, extensions, R&D, bolt-on acquisitions, and margin expansion.

Pfizer is one of the largest pharmaceutical companies in the world. As such, it has scale in R&D, manufacturing, regulatory affairs, distribution, and marketing around the world.

This gives Pfizer the ability to bring new therapies to market, partner with smaller companies, or acquire entire companies outright. The current pipeline is robust, and some will likely be blockbuster drugs even after attrition. As a pharmaceutical company, Pfizer is thought to be recession resistant.

PFE has increased its dividend for 16 years and currently yields 6.5%.

Comcast Corp. (CMCSA)

Comcast is a media, entertainment and communications company. As of Q1 2023, Comcast began reporting in 2 key business segments: Connectivity & Platforms (Residential Connectivity & Platforms and Business Services Connectivity), and Content & Experiences (Media, Studios, Theme Parks).

Comcast reported its Q4 2024 results on Jan. 30th, 2025. The company was able to post resilient results with revenue rising by 2.1% to $31.9 billion year over year. Adjusted EBITDA (a cash flow proxy) was up 10% to $8.8 billion. As well, it increased its adjusted earnings-per-share (EPS) by 14% to $0.96.

And Comcast generated free cash flow (FCF) of $3.3 billion. The Connectivity & Platforms segment’s revenues rose marginally by 0.2% to $20.5 billion. That said, the segment experienced adjusted EBITDA growing marginally by 3.5% to $7.8 billion, helped by margins expansion of 1.2% to 38.3%. The Content & Experiences segment saw revenue grow 5.0% to $12.1 billion, driven by Media and Studios, while its adjusted EBITDA jumped 60% to $1.5 billion.

Full-year 2024 revenue rose 1.8% year over year to $123.7 billion, adjusted EBITDA rose 1.2% to $38.1 billion, and its adjusted EPS climbed 9.0% to $4.33. For the year, Comcast repurchased $8.6 billion worth of common stock at ~$40.60 per share.

Comcast also raised its quarterly dividend by 6.5% to $0.33 per share

Comcast has had 17 consecutive dividend increases. This fast dividend growth was made possible through solid earnings growth and with a safe dividend payout ratio. Its dividend is well-covered by earnings and cash flows. Comcast is one of the largest players in the entertainment industry.

CMCSA stock currently yields 3.6%.

Kenvue Inc. (KVUE)

Kenvue Inc. (KVUE) is a consumer healthcare company that was spun off from Johnson & Johnson. Kenvue has three segments, including Self Care, Skin Health and Beauty, and Essential Health.

Self-Care’s product portfolio includes cough, cold, allergy, smoking cessation, and pain care products among others. Skin Health and Beauty holds products such as face, body, hair, and sun care. Essential Health contains products for women’s health, wound care, oral care, and baby care.

Well-known brands in Kenvue’s product line up include Tylenol, Listerine, Band-Aid, Neutrogena, Nicorette, and Zyrtec. These businesses contributed approximately 17% of Johnson & Johnson’s annual revenue.

While Kenvue is a new, standalone business, it carries Johnson & Johnson’s 60+ year dividend increase streak. On July 25th, 2024, Kenvue announced that it was raising its quarterly dividend 2.5% to $0.205.

On February 6^th, the company released fourth-quarter and full-year financial results. Fourth-quarter net sales declined 0.1% year-over-year, although organic sales increased 1.7%, offset by unfavorable currency translation. Fourth-quarter adjusted diluted earnings per share fell to $0.26 from $0.31 in the prior-year period.

For the full year, net sales rose 0.1% due to organic growth of 1.5%, partially offset by currency translation. Organic sales growth was driven by 2.7% price increases, partially offset by 1.2% volume decline.

KVUE stock currently yields 3.4%.

_______________

Bob Ciura has worked at Sure Dividend since October 2016. He oversees all content for Sure Dividend and its partner sites. Bob received a Bachelor’s degree in Finance from DePaul